Konstantinos Kostikas Selected Research

indacaterol

2/2022	Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
1/2021	Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials.
1/2020	Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
1/2019	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
1/2019	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
12/2018	Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
1/2018	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
1/2018	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
1/2018	Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
1/2018	Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Konstantinos Kostikas Research Topics

Disease

85	Chronic Obstructive Pulmonary Disease (COPD) 11/2022 - 10/2003
31	Asthma (Bronchial Asthma) 10/2022 - 05/2002
16	Inflammation (Inflammations) 04/2021 - 10/2003
8	Dyspnea (Shortness of Breath) 01/2022 - 10/2003
7	COVID-19 10/2022 - 12/2020
7	Pleural Effusion (Pleural Effusions) 02/2018 - 07/2005
6	Emphysema 12/2017 - 02/2010
5	Obstructive Sleep Apnea 12/2022 - 10/2006
4	Eosinophilia 12/2021 - 05/2002
4	Lung Neoplasms (Lung Cancer) 02/2018 - 10/2006
4	Lung Diseases (Lung Disease) 01/2017 - 01/2009
4	Respiratory Insufficiency (Respiratory Failure) 11/2014 - 11/2007
3	Disease Progression 01/2022 - 10/2013
3	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2021 - 01/2009
3	Neoplasms (Cancer) 02/2018 - 05/2009
3	Fibrosis (Cirrhosis) 01/2016 - 01/2010
2	Hypoxia (Hypoxemia) 06/2021 - 01/2014
2	Idiopathic Pulmonary Fibrosis 05/2021 - 10/2006
2	Pneumonia (Pneumonitis) 01/2019 - 01/2009
2	Pleural Diseases 02/2018 - 10/2006
2	Neoplasm Metastasis (Metastasis) 02/2018 - 05/2009
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2016 - 01/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2013 - 12/2011
2	Disorders of Excessive Somnolence (Hypersomnia) 01/2011 - 06/2008
2	Pulmonary Hypertension 05/2009 - 10/2006
1	Pulmonary Embolism 01/2022
1	Cytokine Release Syndrome 11/2021
1	Necrosis 04/2021

Drug/Important Bio-Agent (IBA)

31	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2009
21	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2022 - 01/2016
16	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 02/2022 - 01/2016
15	Bronchodilator Agents (Bronchodilators)IBA 03/2022 - 09/2010
15	indacaterolIBA 02/2022 - 01/2017
11	GoldIBA 11/2021 - 10/2010
10	Fluticasone (Cutivate)FDA LinkGeneric 11/2021 - 01/2017
9	Muscarinic AntagonistsIBA 02/2022 - 01/2017
9	Salmeterol Xinafoate (Serevent)FDA Link 11/2021 - 01/2017
8	Proteins (Proteins, Gene)FDA Link 10/2021 - 02/2013
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 07/2005
6	GasesIBA 01/2022 - 11/2007
6	Tiotropium Bromide (Spiriva)FDA Link 01/2020 - 09/2010
4	Biological ProductsIBA 10/2022 - 10/2019
4	Interleukin-6 (Interleukin 6)IBA 04/2021 - 05/2007
4	Interleukin-8 (Interleukin 8)IBA 01/2017 - 06/2012
4	LeptinIBA 03/2013 - 01/2010
4	AdiponectinIBA 03/2013 - 01/2010
3	SteroidsIBA 03/2022 - 01/2009
3	Uric Acid (Urate)IBA 01/2022 - 01/2014
3	Fibrinogen (Factor I)FDA Link 10/2021 - 02/2010
3	SmokeIBA 01/2021 - 05/2005
3	insulin receptor-related receptor (IRR)IBA 01/2021 - 09/2016
3	OsteopontinIBA 02/2018 - 01/2013
3	Surface-Active Agents (Surfactants)IBA 01/2018 - 01/2016
3	8-epi-prostaglandin F2alphaIBA 04/2011 - 10/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2010 - 05/2007
2	Formoterol Fumarate (Oxis)FDA Link 06/2022 - 03/2022
2	Doxycycline (Periostat)FDA LinkGeneric 01/2022 - 12/2020
2	Blood Coagulation Factors (Coagulation Factor)IBA 10/2021 - 08/2021
2	AcidsIBA 06/2021 - 01/2016
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 01/2021
2	CollagenIBA 10/2018 - 01/2017
2	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2018 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2018 - 06/2012
2	Interleukin-13IBA 01/2017 - 01/2013
2	Tobacco Smoke Pollution (Passive Smoking)IBA 01/2016 - 01/2014
2	AngiopoietinsIBA 01/2015 - 06/2012
2	C-Reactive ProteinIBA 02/2014 - 01/2010
2	Carbon MonoxideIBA 12/2011 - 05/2009
2	Matrix Metalloproteinases (MMPs)IBA 01/2010 - 01/2009
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2009 - 04/2008
1	Retinaldehyde (Retinal)IBA 12/2022
1	mepolizumabIBA 09/2022
1	Budesonide (Pulmicort)FDA LinkGeneric 06/2022
1	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 03/2022
1	GadoliniumIBA 02/2022
1	CreatinineIBA 01/2022
1	tocilizumab (atlizumab)FDA Link 11/2021
1	Protein SIBA 10/2021
1	AntithrombinsIBA 10/2021
1	Lactic Acid (Lactate)FDA LinkGeneric 06/2021
1	Interleukin-1 (Interleukin 1)IBA 04/2021
1	InterleukinsIBA 04/2021
1	Phosphodiesterase 4 InhibitorsIBA 04/2021
1	Mitogen-Activated Protein KinasesIBA 04/2021
1	Interleukin-23 (Interleukin 23)IBA 04/2021
1	Phosphodiesterase 3 InhibitorsIBA 04/2021
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2021
1	Inflammation MediatorsIBA 04/2021
1	Interleukin-17 (Interleukin 17)IBA 04/2021
1	Tyrosine Kinase InhibitorsIBA 04/2021
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 04/2021

Therapy/Procedure

26	Therapeutics 01/2022 - 05/2005
4	Nebulizers and Vaporizers (Inhaler) 03/2022 - 01/2018
3	Drug Therapy (Chemotherapy) 03/2022 - 02/2013
3	Length of Stay 11/2014 - 11/2007
3	Noninvasive Ventilation 01/2011 - 11/2007
2	Continuous Positive Airway Pressure 01/2009 - 07/2006
1	Artificial Respiration (Mechanical Ventilation) 10/2022
1	Activities of Daily Living (ADL) 01/2022
1	Biological Therapy 04/2021